Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | COMT | P21964 | 1/20 | 0.49 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433936 | 0.85 | COMT (0.50) | OPRM1COMTGPR52MAPK14KDM4E | |
| SCHEMBL13216163 | 0.80 | KDM4E (0.43) | OPRM1COMTGPR52MAPK14KDM4E | |
| SCHEMBL12597764 | 0.80 | COMT (0.46) | OPRM1COMTMAPK14PLATTRPA1 | |
| SCHEMBL10271986 | 0.77 | COMT (0.53) | OPRM1COMTMAPK14KDM4EALDH1A1 | |
| SCHEMBL13216162 | 0.77 | SLC6A3 (0.44) | OPRM1COMTKDM4EALDH1A1HPGD | |
| SCHEMBL18550724 | 0.74 | NPY5R (0.47) | OPRM1DHFRKDM4EALDH1A1HPGD | |
| SCHEMBL14364221 | 0.72 | COMT (0.48) | OPRM1COMTMAPK14PLAT | |
| SCHEMBL8205308 | 0.69 | MAPK14 (0.62) | OPRM1COMTMAPK14 | |
| SCHEMBL14960139 | 0.69 | DHFR (0.42) | DHFRTRPA1KDM4EALDH1A1HPGD | |
| SCHEMBL198461 | 0.69 | CSNK2A2 (0.52) | DHFRTRPA1KCNN4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, NAT1 | OPRM1 375/4885COMT 2749/4885GPR52 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.